BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/9/2024 8:41:18 AM | Browse: 137 | Download: 828
 |
Received |
|
2024-06-05 11:05 |
|
Peer-Review Started |
|
2024-06-05 11:05 |
|
First Decision by Editorial Office Director |
|
2024-06-25 10:56 |
|
Return for Revision |
|
2024-06-25 10:56 |
|
Revised |
|
2024-07-03 03:59 |
|
Publication Fee Transferred |
|
2024-07-14 16:24 |
|
Second Decision by Editor |
|
2024-07-09 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-07-09 06:45 |
|
Articles in Press |
|
2024-07-09 06:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-07-29 09:21 |
|
Publish the Manuscript Online |
|
2024-09-09 08:41 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Cheng-Wan Zheng, Yun-Mo Yang and Hui Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hui Yang, MMed, Chief Physician, Department of Thyroid Surgery, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. yh65011@163.com |
| Key Words |
Advanced gastric cancer; Oxaliplatin; Trastuzumab; Serum tumor markers; T lymphocyte subsets; Predictive biomarkers |
| Core Tip |
An investigation of the effects of oxaliplatin and trastuzumab combination therapy on serum tumor markers and T lymphocyte subsets in patients with advanced gastric cancer (AGC) revealed significant reductions in carcinoembryonic antigen, cancer antigen 19-9, and cancer antigen 72-4 levels, as well as favorable changes in T cell populations. Patients with significantly decreased tumor marker levels and increased CD4+/CD8+ ratio exhibited better treatment responses. The therapy not only targets tumors but also boosts immune responses in patients with AGC. Serum markers and T cell subsets are potential predictive biomarkers for treatment outcomes in patients with AGC receiving this combined treatment. |
| Publish Date |
2024-09-09 08:41 |
| Citation |
Zheng CW, Yang YM, Yang H. Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer. World J Gastrointest Oncol 2024; 16(9): 3905-3912 |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i9/3905.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i9.3905 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
